- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.10.24 | Regencell Bioscience Holdings Ltd - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| REGENCELL BIOSCIENCE Aktie jetzt für 0€ handeln | |||||
| 23.07.24 | What Is Going on With Regencell Bioscience (RGC) Stock Today? | 8 | InvestorPlace |
2 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 39,150 | +2,76 % | BB Biotech Aktie: Positiver Blick auf die Zukunft! | Die BB Biotech AG verzeichnet einen positiven Start ins neue Jahr. Der führende Biotechnologie-Investor konnte im ersten Monat 2025 einen Kursanstieg von 1,40 Prozent verbuchen. Mit einem aktuellen... ► Artikel lesen | |
| EPIGENOMICS | 1,080 | -16,92 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 1,048 | -5,42 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,416 | -5,02 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,000 | -5,76 % | Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors | Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics
... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,640 | -3,49 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,910 | -5,61 % | Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts | More Than 40 Adult Sickle Cell Disease Patients Now Enrolled in BEACON Trial of BEAM-101; Beam Expects to Dose 30 Patients and Present Updated Data by Mid-2025 Initial Data from Phase 1/2 Trial of... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,825 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort | Early safety and tolerability results from six randomized patients support continued enrollment of pelareorep combined with modified FOLFIRINOX, with or without... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,840 | -6,39 % | Arcturus Therapeutics (NASDAQ:ARCT) Shares Down 8.6% - Here's Why | ||
| ASSERTIO | 0,800 | -4,35 % | Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,855 | 0,00 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
| VIR BIOTECHNOLOGY | 10,500 | -13,37 % | Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why | ||
| SIGA TECHNOLOGIES | 6,060 | -2,42 % | SIGA Technologies Inc.: TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses | Regulatory decision marks first approval in Japan of an antiviral for the treatment of orthopoxviruses including smallpox, mpox and cowpoxJapan Biotechno Pharma Co., Ltd. engaged as exclusive distributor... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,090 | +1,29 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 5,445 | -1,98 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen |
Das Unternehmen REGENCELL BIOSCIENCE HOLDINGS LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 4,950 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REGENCELL BIOSCIENCE HOLDINGS LIMITED finden Sie auf Wallstreet Online.
